Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy: Radiographic pattern-based approach in waldenström macroglobulinemia as a paradigm

Oncologist

Volumn 20, Issue 9, 2015, Pages 1077-1083

  Nishino, Mizuki ^a   Boswell, Erica N ^a   Hatabu, Hiroto ^a   Ghobrial, Irene M ^a   Ramaiya, Nikhil H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Computed tomography; Drug toxicity; Mammalian target of rapamycin inhibitor; mTOR; Pneumonitis; Waldenstr m macroglobulinemia

Indexed keywords

BORTEZOMIB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; RITUXIMAB; PROTEIN KINASE INHIBITOR; RAPAMYCIN;

ADULT; AGED; ALGORITHM; ARTICLE; BRONCHIECTASIS; BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSESSMENT; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FOLLOW UP; HUMAN; INTERSTITIAL PNEUMONIA; LOW DRUG DOSE; MALE; MEDICAL RECORD REVIEW; PNEUMONIA; PRIORITY JOURNAL; RADIODIAGNOSIS; RESPIRATORY TRACT DISEASE; THORAX RADIOGRAPHY; WALDENSTROEM MACROGLOBULINEMIA; CHEMICALLY INDUCED; DIAGNOSTIC IMAGING; MIDDLE AGED; RADIOGRAPHY; RETROSPECTIVE STUDY; VERY ELDERLY; WALDENSTROM MACROGLOBULINEMIA;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; PROTEIN KINASE INHIBITORS; RADIOGRAPHY; RETROSPECTIVE STUDIES; SIROLIMUS; WALDENSTROM MACROGLOBULINEMIA;

EID: 84940647943     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0033     Document Type: Article

References (28)

1. Erasmus JJ, McAdams HP, Rossi SE. Highresolution CT of drug-induced lung disease. Radiol Clin North Am 2002;40:61-72.
2. Ghobrial IM, Gertz M, Laplant B et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1408-1414.
3. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-456.
4. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renalcell carcinoma. N Engl J Med 2007;356:2271-2281.
5. Witzig TE, Geyer SM, Ghobrial I et al. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005;23: 5347-5356.
6. Ansell SM, Tang H, Kurtin PJ et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: A phase 2 study. Lancet Oncol 2011;12:361-368.
7. Bouabdallah K, Ribrag V, Terriou L et al. Temsirolimus in the treatment of mantle cell lymphoma: Frequency and management of adverse effects. Curr Opin Oncol 2013;25(suppl 2):S1-S12.
8. Willemsen AE, van Herpen CM. mTOR inhibitorrelated pulmonary toxicity; Incidence even higher. Acta Oncol 2013;52:1234.
9. Maroto JP, Hudes G, Dutcher JP et al. Drugrelated pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 2011;29:1750-1756.
10. Dabydeen DA, Jagannathan JP, Ramaiya N et al. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome. Eur J Cancer 2012;48:1519-1524.
11. Atkinson BJ, Cauley DH, Ng C et al. mTOR inhibitor associated noninfectious pneumonitis in patients with renal cell cancer: Management, predictors, and outcomes. BJU Int 2014;113:376-382.
12. Soria JC, Shepherd FA, Douillard JY et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann Oncol 2009;20:1674-1681.
13. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002;165:277-304.
14. Travis WD, Costabel U, Hansell DM et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733-748.
15. Nishino M, Cardarella S, Dahlberg SE et al. Interstitial lung abnormalities in treatment ïve advanced NSCLC patients (pts): Prevalence and impact on survival. J Clin Oncol 2014;32(suppl):e19030a.
16. Nishino M, Cardarella S, Araki T et al. Radiographic interstitial lung abnormalities in advanced NSCLC patients during platinum-based chemotherapy: A systematic study in a cohort with wild-type EGFR, ALK, BRAF, and KRAS. Paper presented at: Annual meeting of the Radiological Society of North America; December 4, 2013; Chicago, IL.
17. Yamaguchi T, Sasaki M, Itoh K. Bortezomibinduced pneumonitis during bortezomib retreatment in multiple myeloma. Jpn J Clin Oncol 2012;42: 637-639.
18. Kang W, Kim JS, Cho SH et al. Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient. Yonsei Med J 2010;51:448-450.
19. Yao CW, Liao WC, Tu CY et al. Rituximabinduced pneumonitis mimicking miliary tuberculosis. Eur Respir Rev 2013;22:587-588.
20. Ergin AB, Fong N, Daw HA. Rituximab-induced bronchiolitis obliterans organizing pneumonia. Case Rep Med 2012;2012:680431
21. Barber NA, Ganti AK. Pulmonary toxicities from targeted therapies: A review. Target Oncol 2011;6:235-243.
22. Arulkumaran N, Suleman R, Cecconi M et al. Rituximab associated pneumonitis in antineutrophil cytoplasmic antibody-associated vasculitis. J Clin Rheumatol 2012;18:39-41.
23. Lota HK, Keir GJ, Hansell DM et al. Novel use of rituximab in hypersensitivity pneumonitis refractory to conventional treatment. Thorax 2013;68: 780-781.
24. Keir GJ, Maher TM, Ming D et al. Rituximab in severe, treatment-refractory interstitial lung disease. Respirology 2014;19:353-359.
25. Duran I, Siu LL, Oza AM et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer 2006;42:1875-1880.
26. Nishino M, Itoh H, Hatabu H. A practical approach to high-resolution CT of diffuse lung disease. Eur J Radiol 2014;83:6-19.
27. Ellis SJ, Cleverley JR, Müller NL. Drug-induced lung disease: High-resolution CT findings. AJR Am J Roentgenol 2000;175:1019-1024.
28. Lynch DA, Travis WD, Müller NL et al. Idiopathic interstitial pneumonias: CT features. Radiology 2005;236:10-21.